- PA5-85197 - Invitrogen Antibodies MMP2 antibody

Xu Y, Yang Q, Fang Z, Tan X, Zhang M, Chen W
Computational and mathematical methods in medicine 2022;2022:6058720

Wang H, Luo Y, Chu Z, Ni T, Ou S, Dai X, Zhang X, Liu Y
Molecules (Basel, Switzerland) 2022 Jun 6;27(11)

Chu Z, Luo Y, Ni T, Zhu M, Feng X, Liu Y, Wang H
Molecules (Basel, Switzerland) 2022 Feb 2;27(3)

Alzahrani AM, Rajendran P, Veeraraghavan VP, Hanieh H
International journal of molecular sciences 2021 Mar 23;22(6)

Li Y, Gong H, Feng L, Mao D, Xiao Y, Wang Y, Huang L
FEBS open bio 2021 Feb;11(2):423-434

Tagliatela AC, Hempstead SC, Hibshman PS, Hockenberry MA, Brighton HE, Pecot CV, Bear JE
Scientific reports 2020 Jul 20;10(1):11958

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunocytochemistry analysis of MMP2 in HeLa cells using MMP2 polyclonal antibody (Product # PA5-85197) at a dilution of 1:200.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: MMP2 Polyclonal Antibody detects MMP2 protein at cytoplasm by immunofluorescent analysis. Sample: U87-MG cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: MMP2 stained by MMP2 Polyclonal Antibody (Product # PA5-85197) diluted at 1:500. Red: alpha Tubulin, a cytoskeleton marker, stained by alpha Tubulin Polyclonal Antibody [GT114] (Product # MA5-31466) diluted at 1:1,000. Blue: Fluoroshield with DAPI .

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation analysis of MMP2 in U87-MG whole cell extracts with MMP2 polyclonal antibody (Product # PA5-85197) using 5 µg of sample, followed by anti-Rabbit IgG secondary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Effects of KRL on DOX-induced hypertrophy. H9c2 cells were treated for 24 h with 15 uM of KRL, 2 h before DOX (0.25 umol) treatment. ( A ) Representative Western blots showing changes in the protein levels of ANP and BNP. ( B ) KRL is illustrated to downregulate MMP9 and MMP2. Western blot analysis was performed to determine the total protein MMP9 and MMp2 levels in the total extract by including beta-actin as an internal loading control. ( C ) H9c2 cells were treated for 24 h with 10 and 15 uM of KRL, 2 h before the DOX (0.25 umol) treatment. The cells then underwent actin filament staining to observe the changes in the surface area of the cardiomyocytes. Scale bar indicated 100u m at 20x magnification. Data are represented as the mean +- SD of triplicate values ( n = 3) and * p < 0.05 represents significant variations compared with the control. # p < 0.05 represents significant variations as compared to DOX alone and KRL with DOX treatment groups.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 5 Fig. CHPF is associated with EMT relative markers and MMP2. (A-D) The GEPIA database was used to analyze the relationship between CHPF and metastatic markers, including vimentin, Snail, Slug and MMP2. (0 < r < 1, Pearson correlation coefficient). (E, F) Effects of CHPF depletion (E) or overexpression (F) on motion-related markers in MCF7 (E) or MDA-MB-231 (F) cells were determined by western blotting. ** P < 0.01 vs. si-con group or vector group. Data are presented as the mean +- SD for three independent experiments. Statistical analyses were performed using Student's t test.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: The bindings between TRIM66 and MMP2 or MMP9. (a) Protein levels of MMP2 and MMP9 in each transfection group. (b) Cells were lysed and immunoprecipitated with antibodies, and immunocomplexes were analyzed by Western blot. (c) MMP9 level in proteins extracted from NSCLC and pulmonary alveolar epithelial cells.

PA5-85197